samedan logo
 
 
 
spacer
home > ebr > Autumn 2019
PUBLICATIONS

European Biopharmaceutical Review

ebr
Autumn 2019

   
Text
PDF
bullet
In Brief
In Brief

Vax Populi

EBR’s Industry Advisor, Emile Bellott, discusses the health achievement of vaccinations against infectious diseases in the post-industrial era, and how immunisation is essential to continue saving millions of lives every year.

 
view
download pdf
bullet
Features
Anti-Idiotypic Antibodies

Robust Method Development for Biologics and Biosimilars

Amanda Turner at Bio-Rad Laboratories examines the factors that enable the demand for biological medicines to evolve and expand, such as the introduction of lower-cost biosimilars, or the ongoing identification of new drug targets.

 
view
download pdf
Preclinical Oncological Research

PET Technology and Tumour Progression

Dr Todd Sasser at Bruker BioSpin writes on how, with the advancements of PET scanning, oncologists are now better able to understand the development of cancers and tumours by better highlighting their morphology and other biomarkers.

 
view
download pdf
Accelerating Process Development

Simply Good Monitoring

Paul Kroll and Alexandra Hofer at Securecell AG articulate how digitisation can accelerate process development in relation to the analysis of liquid samples.
 
view
download pdf
High-Productivity Membrane Chromatography

The Next-Generation Purification of Monoclonal Antibodies

Gary Skarja at Merck examines the key developments in mAb manufacturing, including the benefits that address productivity and cost challenges in a singleuse format.

 
view
download pdf
Challenges in Cellular, Tissue, and Gene Therapy Products

Drug Development Decisions

Cost control in drug development is always at the forefront of manufacturer’s minds, and Zeb Younes and Zaklina Buljovcic at PharmaLex examine how automation and decentralising the manufacturing process can help achieve this goal in the long run.
 
view
download pdf
Developments in Artificial Intelligence

Focusing on Target Safety

Although in its infancy, Ruth Roberts at ApconiX describes how artificial intelligence can help reduce the cost and the amount of product failures in regard to drug development and creation.
 
view
download pdf
Standardising Conditions for Extractables Testing

Exhaustive Extraction

Simone Carrara and Michele Vasso at Eurofins illustrate the importance of extractables and leachables to ensure drug efficacy, and that the product remains in optimal condition to interact with the patient.
 
view
download pdf
bullet Stem Cell Research
Stem Cell Therapy

Recombinant Human Albumin

Cryopreservation and stem cell therapies are facing major changes and advancements, Dr Phil Morton and Dr Daniel Shelly at Albumedix discuss how albumin is useful across the cell therapy value chain.


 
view
download pdf
Live Cell Transport

The Rising Star

The way in which we transport existing cell shipments is continuously being optimised, and Dr Corné Swart at Cellbox Solutions looks into these new devices that allow cells to survive compared to traditional methods.
 
view
download pdf
bullet
rare diseases
Orphan Drugs and Rare Diseases

Patient Voices in the Industry

When considering the development of orphan drugs, the patients that suffer from the diseases and help process drug development in clinical trials also have to be considered, write William C Maier and Kelly Franchetti at ICON.
 
view
download pdf
bullet
dna and rna sequencing
Biopharmaceutical Applications

The Advantages of Long-Read Sequencing

Jonas Korlach at Pacific Biosciences discusses the improvements in long-read sequencing technology, and the applications it may have in the discovery of new drugs.
 
view
download pdf
Advances in Oncology

Advancing Liquid Biopsies

Mark Li at Resolution Bioscience examines why liquid biopsies are now becoming more commonly used compared to tissue biopsies.
 
view
download pdf
bullet
cannabis-based drugs
The Potential of Medical Cannabis

Budding Opportunities for Pharma

Shifting attitudes towards cannabis-based medicines are making them more appealing to drug developers, which will in turn help patients who need these drugs, writes Callum McGuinn at Mewburn Ellis.
 
view
download pdf
The Future of Clinical Research on Medical Cannabis

Trial by Fire

Dr Mark A Ware at Canopy Growth Corporation describes the changes in drug policy in recent times surrounding cannabis-based drugs, and the advantages they may have in treating patients.
 
view
download pdf
   
spacer


Published quarterly in
January, April,
July, and October

News and Press Releases

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

• 3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use • Beginning of Phase I clinical trial in a group of 10 patients
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

Industry Events

CPhI Festival of Pharma

5-16 October 2020, Virtual

A virtual gathering for the pharmaceutical industry, the CPhI Festival of Pharma has been created to fill the gap left by in-person events at a time when travel and gatherings are off the cards.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement